Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • scottdaniel
    Junior Member
    • Apr 2012
    • 9

    Read runs and technical replicates

    So I've downloaded some example data from SRA archives at http://www.ncbi.nlm.nih.gov/sra?term=SRA011001 and had a question about technical and biological replicates (see attached picture for a snapshot of the downloads). I know that there are two biological replicates for control and treatment conditions (in this case a miR155 over-expression retrovirus) but I'm not sure about the technical replicates.

    Do read runs count as technical replicates?

    And, if so, how can I use that in my analysis pipeline (currently I'm using the Tuxedo suite (i.e. tophat > cufflinks > cuffmerge, etc.)).

    Right now I think I'm just telling the program that there are six biological replicates of each condition (i.e. 6 x miR155oe vs. 6 x control) which is probably wrong.

    Thanks, Scott
    Attached Files
  • chadn737
    Senior Member
    • Jan 2009
    • 392

    #2
    It has been shown in many cases that Biological variation is far greater than technical variation in Illumina sequencing and typically individual runs are pooled together and treated as one sample. Ideally thats why you multiplex all your biological replicates and spread the sequencing across multiple lanes.

    Comment

    • scottdaniel
      Junior Member
      • Apr 2012
      • 9

      #3
      Originally posted by chadn737 View Post
      It has been shown in many cases that Biological variation is far greater than technical variation in Illumina sequencing and typically individual runs are pooled together and treated as one sample. Ideally thats why you multiplex all your biological replicates and spread the sequencing across multiple lanes.
      Is there paper where this is shown?

      So perhaps I should merge my .sam files per biological replicate and then do the tophat/bowtie alignment?

      Thanks.

      Comment

      • chadn737
        Senior Member
        • Jan 2009
        • 392

        #4
        Marioni, J. C., C. E. Mason, S. M. Mane, M. Stephens and Y. Gilad,
        2008 RNA-Seq: an assessment of technical reproducibility and
        comparison with gene expression arrays. Genome Res. 18: 1509–1517.

        Comment

        Latest Articles

        Collapse

        • mylaser
          Reply to Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
          by mylaser
          Kheloyar – Everything You Need to Know About Kheloyaar Login and Kheoyar Id
          If you are looking for an online gaming platform that offers a user-friendly experience, Kheloyar has become a name that many users search for. Whether you're interested in creating a new account, accessing your dashboard through Kheloyaar Login, or learning how to obtain a Kheoyar Id, understanding the platform's features and account process is essential.
          This guide explains everything you need to know about...
          Yesterday, 01:13 AM
        • SEQadmin2
          Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
          by SEQadmin2



          Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
          ...
          07-09-2026, 11:10 AM
        • SEQadmin2
          Cancer Drug Resistance: The Lingering Barrier to Rising Survival
          by SEQadmin2



          Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

          There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
          07-08-2026, 05:17 AM

        ad_right_rmr

        Collapse

        News

        Collapse

        Topics Statistics Last Post
        Started by SEQadmin2, 07-09-2026, 10:04 AM
        0 responses
        19 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 07-08-2026, 10:08 AM
        0 responses
        11 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 07-07-2026, 11:05 AM
        0 responses
        26 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 07-02-2026, 11:08 AM
        0 responses
        31 views
        0 reactions
        Last Post SEQadmin2  
        Working...